New drug with standard targeted therapy for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new drug (BG-C9074) combined with a standard targeted therapy (bevacizumab) for women newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding this new drug can help shrink or control the cancer better than the standard approach alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with high-grade ovarian, fallopian tube, or primary peritoneal cancer (common types: serous, endometrioid, or clear cell).
- Your cancer is stage III or IV, meaning it has spread within the abdomen or beyond.
- You've had surgery to remove the tumor (debulking), either as first treatment or after a few chemotherapy sessions.
- You are physically able to care for yourself (up and about, but not necessarily fully active).
- Your organ function (like kidneys, liver, blood counts) is adequate, as determined by tests.
- You do not have a BRCA gene mutation, and you are not planning to take a PARP inhibitor as maintenance therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
This trial tests a new drug combination (torvutatug samrotecan plus bevacizumab) as maintenance therapy to help keep advanced ovarian cancer from growing after initial chemotherapy. It is for people whose tumors do not have a specific genetic change called HRD.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.